{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:08:35Z","timestamp":1773050915784,"version":"3.50.1"},"reference-count":19,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2016.00168","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T03:08:09Z","timestamp":1467947289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure"],"prefix":"10.3389","volume":"6","author":[{"given":"Alan","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia C.","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"issue":"1","key":"B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"issue":"5","key":"B2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/153303460900800509","article-title":"Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer","volume":"8","author":"Friedland","year":"2009","journal-title":"Technol Cancer Res Treat"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes","volume":"6","author":"Freeman","year":"2011","journal-title":"Radiat Oncol"},{"issue":"1","key":"B4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1748-717X-8-118","article-title":"Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years","volume":"8","author":"Katz","year":"2013","journal-title":"Radiat Oncol"},{"issue":"15","key":"B5","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"issue":"15","key":"B6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-9-1","article-title":"Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study","volume":"9","author":"Katz","year":"2014","journal-title":"Radiat Oncol"},{"issue":"1","key":"B10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1999.17.1.168","article-title":"Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer","volume":"17","author":"D\u2019Amico","year":"1999","journal-title":"J Clin Oncol"},{"key":"B11","author":"Guidelines","year":"2016","journal-title":"Prostate Cancer.1"},{"issue":"4","key":"B12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"B13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/153303460600500410","article-title":"Image-guided radiosurgical ablation of intra- and extra-cranial lesions","volume":"5","author":"Romanelli","year":"2006","journal-title":"Technol Cancer Res Treat"},{"key":"B14","first-page":"965","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","author":"Roach","year":"2006"},{"issue":"6","key":"B15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"issue":"5","key":"B16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"B17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0360-3016(03)00009-9","article-title":"The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy","volume":"56","author":"Potters","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"B18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.eururo.2015.08.054","article-title":"Gleason score 3 + 5 or 5 + 3 versus 4 + 4 prostate cancer: the risk of death","volume":"69","author":"Huynh","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"B19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","article-title":"What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation","volume":"115","author":"Zaorsky","year":"2015","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T21:47:01Z","timestamp":1568152021000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fonc.2016.00168\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":19,"URL":"https:\/\/doi.org\/10.3389\/fonc.2016.00168","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,8]]}}}